A Phase II, Randomized, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Efficacy, Safety, and Tolerability of Single Doses of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae
Phase of Trial: Phase II
Latest Information Update: 27 May 2017
At a glance
- Drugs Gepotidacin (Primary)
- Indications Gonorrhoea
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 29 Sep 2016 Status changed from recruiting to completed.
- 09 Jun 2016 Planned End Date changed from 1 Mar 2016 to 1 Jul 2016.
- 09 Jun 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jul 2016.